IRWD : Summary for Ironwood Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets close in 2 hrs 31 mins

Ironwood Pharmaceuticals, Inc. (IRWD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.46-0.19 (-1.30%)
As of 1:28PM EST. Market open.
People also watch
INFIAEGRRPTPSGYPMNTA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close14.65
Open14.67
Bid14.35 x 200
Ask14.37 x 800
Day's Range14.05 - 14.79
52 Week Range7.35 - 16.89
Volume1,437,362
Avg. Volume1,292,588
Market Cap2.11B
Beta1.05
PE Ratio (TTM)-25.32
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Ironwood Pharmaceuticals, Inc. (IRWD) Has A Near Term Catalyst To Watch
    Insider Monkey1 hour ago

    Ironwood Pharmaceuticals, Inc. (IRWD) Has A Near Term Catalyst To Watch

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has a PDUFA date of February 9, 2017 for the the company’s 72 mcg dose of its chronic idiopathic constipation (CIC) candidate, Linzess (linaclotide). The drug is already approved in its present indication, but currently, because of its high dose (145 mcg), it is not being used to treat more mild […]

  • Reuters2 hours ago

    UPDATE 1-Synergy wins U.S. approval for constipation drug (Jan 19)

    The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC). CIC, which affects 14 percent of the global population, is a type of gastrointestinal disorder where individuals have difficult and infrequent bowel movements. Trulance met the main goals of two late-stage studies in December on irritable bowel syndrome patients with constipation (IBS-C).

  • TheStreet.com4 days ago

    Synergy Pharmaceuticals Secures Approval for Linzess Competitor

    New bowel drug Trulance will be available for patients later this quarter.